Debra Hughes, MS, Author at Oncology Nurse Advisor - Page 3 of 12

Debra Hughes, MS

Debra Hughes is a medical writer based in Lusby, Maryland.

All articles by Debra Hughes, MS

Nimotuzumab + Radiotherapy Less Toxic Than Cisplatin + Radiotherapy for Stage III/IVB Nasopharyngeal Cancer

Patients with locally advanced nasopharyngeal cancer concurrently treated with nimotuzumab and radiotherapy had similar rates of progression-free and overall survival to those treated with cisplatin and radiotherapy, but with significantly fewer GI and hematologic toxicities, according to phase 3 trial results presented at the ASCO 2016 Annual Meeting.

Cisplatin, Cetuximab Show Similar Locoregional Control in Unresectable Head and Neck Cancer

Survival results from the first randomized phase 3 trial to compare cisplatin-radiotherapy with cetuximab-radiotherapy after induction chemotherapy in patients with locally advanced unresectable head and neck cancer remain inconclusive, with both arms showing good locoregional control, greater than 50% at 3 years, attendees at the ASCO 2016 Annual Meeting were told.

Utidelone Plus Capecitabine Active in Patients Heavily Pretreated for Metastatic Breast Cancer

The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.

Next post in ASCO 2016 Annual Meeting